愿景控股公司与中国的Yike公司合作,推进细胞恢复研究,重点是干细胞和医学美学智能送货系统。 Visionary Holdings partners with China’s Yike to advance cellular rejuvenation research, focusing on stem cells and smart delivery systems for medical aesthetics.

愿景控股公司(GV)与中国江苏Yike Remedication Medicines(江苏Yike Repecial Medicine)合作,推进细胞恢复活力和美学治疗研究。 Visionary Holdings (GV) has partnered with China’s Jiangsu Yike Regenerative Medicine to advance research in cellular rejuvenation and aesthetic treatments. Yike将领导研发工作并为工作提供资金,而GV将评估结果,并可以通过现金或股票获得或许可权利。 Yike will lead R&D and fund the work, while GV will assess results and may acquire or license rights through cash or stock. 合作的重点是细胞激活、智能投送系统和干细胞应用,目的是在医学美学行业进行创新。 The collaboration focuses on cell activation, smart delivery systems, and stem cell applications, aiming to innovate in the medical aesthetics industry.